VarmX, a biotechnology company focused on the development of therapies to reverse blood coagulation, named Jeffery Lawson, MD, PhD, its chief scientific officer.
Dr. Lawson most recently served as president and CEO of Humacyte, a regenerative medicine company, according to a March 8 news release from VarmX. He previously served as director of clinical trials for the department of surgery at Duke University Medical Center in Durham, N.C.
Dr. Lawson is succeeding Pieter Reitsma, PhD, founder of VarmX, who will serve as special adviser to the company's board, the release said.